MedTrace Logo

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

NCT03252171 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2020-07-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.

Conditions

  • GD2 Positive Glioma
  • CAR-T Cell Immunotherapy

Interventions

BIOLOGICAL

CAR-T cell immunotherapy

This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen.

Sponsors & Collaborators

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Lizhi Niu, PhD · Fuda Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-15
Primary Completion
2016-08-15
Completion
2016-08-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03252171 on ClinicalTrials.gov